Logo

BMS Reports EMA's Validation of MAA for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + CT to Treat Esophageal Squamous Cell Carcinoma

Share this

BMS Reports EMA's Validation of MAA for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + CT to Treat Esophageal Squamous Cell Carcinoma

Shots:

  • The applications are based on P-III CheckMate -648 trial evaluates Opdivo (3 mg/kg- q2w) + Yervoy (1 mg/kg- q6w up to 24mos.) or Opdivo (nivolumab) + CT vs CT alone in patients with unresectable advanced or metastatic ESCC
  • Results: Both combinations showed OS benefit over CT at the pre-specified interim analysis in patients with tumor cell PD-L1 expression ≥1% & all-randomized population while safety profiles were consistent with the known safety profiles of the individual components
  • The MAA validation confirms that the submissions are complete- and the EMA will now initiate the review procedure. The results were presented at ASCO 2021

 Ref: Businesswire | Image: BMS 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions